Cooper, Dan, et al. “A POPULATION-BASED COST-EFFECTIVENESS ANALYSIS OF OLANZAPINE AND RISPERIDONE AMONG AMBULATORY PATIENTS WITH SCHIZOPHRENIA”. Journal of Population Therapeutics and Clinical Pharmacology, vol. 15, no. 3, Dec. 2018, https://mail.jptcp.com/index.php/jptcp/article/view/229.